# Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.

> **NCT05060887** · PHASE2 · COMPLETED · sponsor: **Osivax** · enrollment: 239 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** OVX836-003
- **BIOLOGICAL:** Saline solution

## Key facts

- **NCT ID:** NCT05060887
- **Lead sponsor:** Osivax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-15
- **Primary completion:** 2022-02-01
- **Final completion:** 2022-12-07
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2023-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05060887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05060887, "Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05060887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*